StockData
Avalyn Pharma Inc. logo

Avalyn Pharma Inc. (AVLN) stock

AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)

Close on Nov 17, 2026Market cap $1.24BP/E –Yield –

Earnings

Avalyn Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Avalyn Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026Jun 3, 2026before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Avalyn Pharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Avalyn Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Avalyn Pharma filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?